Retrospective study on the safety and efficacy of pyrotinib in the treatment of HER2positive non-breast advanced solid tumors.

被引：0
|
作者：
Wang, Jianzheng
Zhang, Baiwen
Cheng, Xiaojiao
Li, Qingli
Lv, Huifang
Nie, Caiyun
Chen, Beibei
Xu, Weifeng
Zhao, Jing
He, Yunduan
Tu, Shuiping
Chen, Xiaobing
机构：
[1] Zhengzhou Univ, Henan Canc Hosp, Dept Gastrointestinal Med Oncol, Affiliated Canc Hosp, Zhengzhou, Peoples R China
[2] Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Dept Oncol, Shanghai, Peoples R China
[3] Zheng zhou Univ, Henan Canc Hosp, Dept Med Oncol, Affiliated Canc Hosp, Zhengzhou, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
15064
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Efficacy and safety of neoadjuvant pyrotinib plus docetaxel/liposomal doxorubicin/cyclophosphamide for HER2-positive breast cancer
    Tian, Chunyu
    Wang, Minghui
    Liu, Hancheng
    Liu, Jianping
    Xu, Mengze
    Ma, Lihui
    IRISH JOURNAL OF MEDICAL SCIENCE, 2023, 192 (03) : 1041 - 1049
  • [32] A Multicenter, Retrospective, Real World Study of Inetetamab Combined with Pyrotinib and Vinorelbine as Treatment for HER2-positive Metastatic Breast Cancer
    Yin, Yongmei
    Li, Wei
    Huang, Xiang
    Jin, Nan
    Wu, Xinyu
    Sun, Chunxiao
    Hua, Yijia
    CANCER RESEARCH, 2024, 84 (09)
  • [33] The HER2-targeting ADC SHR-A1811 in HER2-expressing/mutated advanced non-breast solid tumors (STs): Results from the global phase I study
    Yao, H.
    Ryu, M. H.
    Park, J.
    Voskoboynik, M.
    Kim, J. H.
    Liu, K.
    Barve, M.
    Acuna-Villaorduna, A.
    Im, S-A.
    Roy, A. C.
    Bai, L-Y.
    Yen, C-J.
    Zhang, J.
    Ganju, V.
    Wu, L.
    Yan, M.
    Bao, L.
    Zhao, Y.
    Rong, S.
    Song, E.
    ANNALS OF ONCOLOGY, 2023, 34 : S461 - S462
  • [34] Pyrotinib in the treatment of women with advanced HER2 positive breast cancer: A multicenter, prospective, real-world study.
    Feng, Jifeng
    Zhang, Lili
    Wu, Xiaohong
    Zhou, Jun
    Zhu, Mingzhen
    Zhang, Yusong
    Yu, Hao
    Han, Zhengxiang
    Guo, Yujiang
    Guan, Xiaoqing
    Wang, Xufen
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [35] Safety and efficacy study of oral metronomic capecitabine combined with pyrotinib in HER2-positive metastatic breast cancer: A phase II trial
    He, Maiyue
    Liu, Jiaxuan
    Wang, Zijing
    Ma, Fei
    Wang, Jiayu
    Zhang, Pin
    Li, Qing
    Yuan, Peng
    Luo, Yang
    Fan, Ying
    Mo, Hongnan
    Lan, Bo
    Li, Qiao
    Xu, Binghe
    BREAST, 2023, 72
  • [36] Safety and efficacy study of oral metronomic capecitabine in combination with pyrotinib for HER2-positive metastatic breast cancer: A phase II trial
    Li, Qiao
    He, Maiyue
    Liu, Jiaxuan
    Wang, Zijing
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [37] Clinical efficacy of pyrotinib combined with chemotherapy for neoadjuvant treatment in HER2-positive breast cancer: a single-center study
    Wei, Benkai
    Yan, Huanhuan
    Li, Fan
    Shen, Jun
    ANTI-CANCER DRUGS, 2025, 36 (04) : 347 - 354
  • [38] Efficacy and safety of pyrotinib-based therapy in the treatment of HER2-positive breast cancer patients with brain metastases:a multi- center realworld study
    Li, Huihui
    Huang, Jie
    Tan, Qiaorui
    Man, Xiaochu
    Yin, Sha
    Sun, Shujuan
    Hu, Yu
    Li, Wenhuan
    Zhou, Dongdong
    Song, Lihua
    Zhang, Baoxuan
    Xu, Liang
    Wang, Xinzhao
    Xie, Xuemei
    CANCER RESEARCH, 2023, 83 (05)
  • [39] Mechanism, safety and efficacy of three tyrosine kinase inhibitors lapatinib, neratinib and pyrotinib in HER2-positive breast cancer
    Xuhong, Jun-Cheng
    Qi, Xiao-Wei
    Zhang, Yi
    Jiang, Jun
    AMERICAN JOURNAL OF CANCER RESEARCH, 2019, 9 (10): : 2103 - 2119
  • [40] Whether HER2-positive non-breast cancers are candidates for treatment with Ado-trastuzumab emtansine
    Moghaddas, Azadeh
    Borhani, Ali
    JOURNAL OF RESEARCH IN PHARMACY PRACTICE, 2016, 5 (04) : 227 - 233
12345